{"entity":{"type":"insider","cik":"0001679129","url":"/insider/0001679129","json_url":"/insider/0001679129.json","name":"PRASAD SUYASH","name_source":"as-filed","also_issuer":false,"cross_url":null},"coverage_statement":{"n_transactions":28,"n_filings":11,"first":"2017-09-01","last":"2022-07-07","span_basis":"filed_date"},"name_variants":[{"name":"PRASAD SUYASH","source":"filing","n_filings":11,"first_seen":"2017-09-01","last_seen":"2022-07-07"}],"transactions":[{"id":6956364,"accession":"0001209191-22-041455","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001209191-22-041455","line_url":"/filing/0001209191-22-041455#line-2","is_derivative":false,"issuer_cik":"0001679129","issuer_name":"Taysha Gene Therapies, Inc.","issuer_ticker":"TSHA","issuer_name_source":null,"issuer_url":"/issuer/0001679129","owner_cik":"0001679129","owner_name":"PRASAD SUYASH","owner_url":"/insider/0001679129","role":"Officer (CMO and Head of R&D)","officer_title":"CMO and Head of R&D","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":8956.0,"shares_display":"8,956","price_per_share":3.79,"price_display":"3.79","price_state":"stated","total_value":33943.24,"total_display":"33,943.24","shares_owned_after":530589.0,"shares_owned_after_display":"530,589","ownership_form":"D","is_10b5_1":null,"transaction_date":"2022-07-06","filed_date":"2022-07-07","scope":"insider"},{"id":6956361,"accession":"0001209191-22-041455","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001209191-22-041455","line_url":"/filing/0001209191-22-041455#line-1","is_derivative":false,"issuer_cik":"0001679129","issuer_name":"Taysha Gene Therapies, Inc.","issuer_ticker":"TSHA","issuer_name_source":null,"issuer_url":"/issuer/0001679129","owner_cik":"0001679129","owner_name":"PRASAD SUYASH","owner_url":"/insider/0001679129","role":"Officer (CMO and Head of R&D)","officer_title":"CMO and Head of R&D","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":3905.0,"shares_display":"3,905","price_per_share":3.51,"price_display":"3.51","price_state":"stated","total_value":13706.55,"total_display":"13,706.55","shares_owned_after":539545.0,"shares_owned_after_display":"539,545","ownership_form":"D","is_10b5_1":null,"transaction_date":"2022-07-05","filed_date":"2022-07-07","scope":"insider"},{"id":6304973,"accession":"0001209191-22-040356","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001209191-22-040356","line_url":"/filing/0001209191-22-040356#line-3","is_derivative":false,"issuer_cik":"0001679129","issuer_name":"Taysha Gene Therapies, Inc.","issuer_ticker":"TSHA","issuer_name_source":null,"issuer_url":"/issuer/0001679129","owner_cik":"0001679129","owner_name":"PRASAD SUYASH","owner_url":"/insider/0001679129","role":"Officer (CMO and Head of R&D)","officer_title":"CMO and Head of R&D","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":23923.0,"shares_display":"23,923","price_per_share":3.53,"price_display":"3.53","price_state":"stated","total_value":84448.19,"total_display":"84,448.19","shares_owned_after":543450.0,"shares_owned_after_display":"543,450","ownership_form":"D","is_10b5_1":null,"transaction_date":"2022-07-01","filed_date":"2022-07-01","scope":"insider"},{"id":6304969,"accession":"0001209191-22-040356","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001209191-22-040356","line_url":"/filing/0001209191-22-040356#line-2","is_derivative":false,"issuer_cik":"0001679129","issuer_name":"Taysha Gene Therapies, Inc.","issuer_ticker":"TSHA","issuer_name_source":null,"issuer_url":"/issuer/0001679129","owner_cik":"0001679129","owner_name":"PRASAD SUYASH","owner_url":"/insider/0001679129","role":"Officer (CMO and Head of R&D)","officer_title":"CMO and Head of R&D","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":13892.0,"shares_display":"13,892","price_per_share":3.72,"price_display":"3.72","price_state":"stated","total_value":51678.24,"total_display":"51,678.24","shares_owned_after":567373.0,"shares_owned_after_display":"567,373","ownership_form":"D","is_10b5_1":null,"transaction_date":"2022-06-30","filed_date":"2022-07-01","scope":"insider"},{"id":6304965,"accession":"0001209191-22-040356","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001209191-22-040356","line_url":"/filing/0001209191-22-040356#line-1","is_derivative":false,"issuer_cik":"0001679129","issuer_name":"Taysha Gene Therapies, Inc.","issuer_ticker":"TSHA","issuer_name_source":null,"issuer_url":"/issuer/0001679129","owner_cik":"0001679129","owner_name":"PRASAD SUYASH","owner_url":"/insider/0001679129","role":"Officer (CMO and Head of R&D)","officer_title":"CMO and Head of R&D","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":12324.0,"shares_display":"12,324","price_per_share":3.81,"price_display":"3.81","price_state":"stated","total_value":46954.44,"total_display":"46,954.44","shares_owned_after":581265.0,"shares_owned_after_display":"581,265","ownership_form":"D","is_10b5_1":null,"transaction_date":"2022-06-29","filed_date":"2022-07-01","scope":"insider"},{"id":5251532,"accession":"0001209191-21-044563","txn_seq":7,"anchor":"line-7","filing_url":"/filing/0001209191-21-044563","line_url":"/filing/0001209191-21-044563#line-7","is_derivative":false,"issuer_cik":"0001679129","issuer_name":"Taysha Gene Therapies, Inc.","issuer_ticker":"TSHA","issuer_name_source":null,"issuer_url":"/issuer/0001679129","owner_cik":"0001679129","owner_name":"PRASAD SUYASH","owner_url":"/insider/0001679129","role":"Officer (CMO and Head of R&D)","officer_title":"CMO and Head of R&D","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":19706.0,"shares_display":"19,706","price_per_share":21.12,"price_display":"21.12","price_state":"stated","total_value":416190.72,"total_display":"416,190.72","shares_owned_after":593589.0,"shares_owned_after_display":"593,589","ownership_form":"D","is_10b5_1":null,"transaction_date":"2021-07-01","filed_date":"2021-07-01","scope":"insider"},{"id":5251529,"accession":"0001209191-21-044563","txn_seq":6,"anchor":"line-6","filing_url":"/filing/0001209191-21-044563","line_url":"/filing/0001209191-21-044563#line-6","is_derivative":false,"issuer_cik":"0001679129","issuer_name":"Taysha Gene Therapies, Inc.","issuer_ticker":"TSHA","issuer_name_source":null,"issuer_url":"/issuer/0001679129","owner_cik":"0001679129","owner_name":"PRASAD SUYASH","owner_url":"/insider/0001679129","role":"Officer (CMO and Head of R&D)","officer_title":"CMO and Head of R&D","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":13374.0,"shares_display":"13,374","price_per_share":21.42,"price_display":"21.42","price_state":"stated","total_value":286471.08,"total_display":"286,471.08","shares_owned_after":619997.0,"shares_owned_after_display":"619,997","ownership_form":"D","is_10b5_1":null,"transaction_date":"2021-06-30","filed_date":"2021-07-01","scope":"insider"},{"id":5251526,"accession":"0001209191-21-044563","txn_seq":5,"anchor":"line-5","filing_url":"/filing/0001209191-21-044563","line_url":"/filing/0001209191-21-044563#line-5","is_derivative":false,"issuer_cik":"0001679129","issuer_name":"Taysha Gene Therapies, Inc.","issuer_ticker":"TSHA","issuer_name_source":null,"issuer_url":"/issuer/0001679129","owner_cik":"0001679129","owner_name":"PRASAD SUYASH","owner_url":"/insider/0001679129","role":"Officer (CMO and Head of R&D)","officer_title":"CMO and Head of R&D","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":6202.0,"shares_display":"6,202","price_per_share":22.44,"price_display":"22.44","price_state":"stated","total_value":139172.88,"total_display":"139,172.88","shares_owned_after":613795.0,"shares_owned_after_display":"613,795","ownership_form":"D","is_10b5_1":null,"transaction_date":"2021-06-30","filed_date":"2021-07-01","scope":"insider"},{"id":5251523,"accession":"0001209191-21-044563","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0001209191-21-044563","line_url":"/filing/0001209191-21-044563#line-4","is_derivative":false,"issuer_cik":"0001679129","issuer_name":"Taysha Gene Therapies, Inc.","issuer_ticker":"TSHA","issuer_name_source":null,"issuer_url":"/issuer/0001679129","owner_cik":"0001679129","owner_name":"PRASAD SUYASH","owner_url":"/insider/0001679129","role":"Officer (CMO and Head of R&D)","officer_title":"CMO and Head of R&D","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":500.0,"shares_display":"500","price_per_share":23.7,"price_display":"23.70","price_state":"stated","total_value":11850.0,"total_display":"11,850.00","shares_owned_after":613295.0,"shares_owned_after_display":"613,295","ownership_form":"D","is_10b5_1":null,"transaction_date":"2021-06-30","filed_date":"2021-07-01","scope":"insider"},{"id":5251520,"accession":"0001209191-21-044563","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001209191-21-044563","line_url":"/filing/0001209191-21-044563#line-3","is_derivative":false,"issuer_cik":"0001679129","issuer_name":"Taysha Gene Therapies, Inc.","issuer_ticker":"TSHA","issuer_name_source":null,"issuer_url":"/issuer/0001679129","owner_cik":"0001679129","owner_name":"PRASAD SUYASH","owner_url":"/insider/0001679129","role":"Officer (CMO and Head of R&D)","officer_title":"CMO and Head of R&D","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":35056.0,"shares_display":"35,056","price_per_share":23.74,"price_display":"23.74","price_state":"stated","total_value":832229.44,"total_display":"832,229.44","shares_owned_after":637533.0,"shares_owned_after_display":"637,533","ownership_form":"D","is_10b5_1":null,"transaction_date":"2021-06-29","filed_date":"2021-07-01","scope":"insider"},{"id":5251517,"accession":"0001209191-21-044563","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001209191-21-044563","line_url":"/filing/0001209191-21-044563#line-2","is_derivative":false,"issuer_cik":"0001679129","issuer_name":"Taysha Gene Therapies, Inc.","issuer_ticker":"TSHA","issuer_name_source":null,"issuer_url":"/issuer/0001679129","owner_cik":"0001679129","owner_name":"PRASAD SUYASH","owner_url":"/insider/0001679129","role":"Officer (CMO and Head of R&D)","officer_title":"CMO and Head of R&D","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":3862.0,"shares_display":"3,862","price_per_share":24.46,"price_display":"24.46","price_state":"stated","total_value":94464.52,"total_display":"94,464.52","shares_owned_after":633671.0,"shares_owned_after_display":"633,671","ownership_form":"D","is_10b5_1":null,"transaction_date":"2021-06-29","filed_date":"2021-07-01","scope":"insider"},{"id":5251514,"accession":"0001209191-21-044563","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001209191-21-044563","line_url":"/filing/0001209191-21-044563#line-1","is_derivative":false,"issuer_cik":"0001679129","issuer_name":"Taysha Gene Therapies, Inc.","issuer_ticker":"TSHA","issuer_name_source":null,"issuer_url":"/issuer/0001679129","owner_cik":"0001679129","owner_name":"PRASAD SUYASH","owner_url":"/insider/0001679129","role":"Officer (CMO and Head of R&D)","officer_title":"CMO and Head of R&D","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":300.0,"shares_display":"300","price_per_share":25.19,"price_display":"25.19","price_state":"stated","total_value":7557.0,"total_display":"7,557.00","shares_owned_after":633371.0,"shares_owned_after_display":"633,371","ownership_form":"D","is_10b5_1":null,"transaction_date":"2021-06-29","filed_date":"2021-07-01","scope":"insider"},{"id":8694152,"accession":"0001209191-19-030040","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001209191-19-030040","line_url":"/filing/0001209191-19-030040#line-3","is_derivative":false,"issuer_cik":"0001628738","issuer_name":"Audentes Therapeutics, Inc.","issuer_ticker":"BOLD","issuer_name_source":null,"issuer_url":"/issuer/0001628738","owner_cik":"0001679129","owner_name":"PRASAD SUYASH","owner_url":"/insider/0001679129","role":"Officer (Senior VP & Chief Med Officer)","officer_title":"Senior VP & Chief Med Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":9946.0,"shares_display":"9,946","price_per_share":36.9758,"price_display":"36.98","price_state":"stated","total_value":367761.3068,"total_display":"367,761.31","shares_owned_after":18290.0,"shares_owned_after_display":"18,290","ownership_form":"D","is_10b5_1":null,"transaction_date":"2019-05-13","filed_date":"2019-05-15","scope":"insider"},{"id":8694148,"accession":"0001209191-19-030040","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001209191-19-030040","line_url":"/filing/0001209191-19-030040#line-2","is_derivative":false,"issuer_cik":"0001628738","issuer_name":"Audentes Therapeutics, Inc.","issuer_ticker":"BOLD","issuer_name_source":null,"issuer_url":"/issuer/0001628738","owner_cik":"0001679129","owner_name":"PRASAD SUYASH","owner_url":"/insider/0001679129","role":"Officer (Senior VP & Chief Med Officer)","officer_title":"Senior VP & Chief Med Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":54.0,"shares_display":"54","price_per_share":37.72,"price_display":"37.72","price_state":"stated","total_value":2036.88,"total_display":"2,036.88","shares_owned_after":18236.0,"shares_owned_after_display":"18,236","ownership_form":"D","is_10b5_1":null,"transaction_date":"2019-05-13","filed_date":"2019-05-15","scope":"insider"},{"id":8389713,"accession":"0001209191-19-014074","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001209191-19-014074","line_url":"/filing/0001209191-19-014074#line-2","is_derivative":false,"issuer_cik":"0001628738","issuer_name":"Audentes Therapeutics, Inc.","issuer_ticker":"BOLD","issuer_name_source":null,"issuer_url":"/issuer/0001628738","owner_cik":"0001679129","owner_name":"PRASAD SUYASH","owner_url":"/insider/0001679129","role":"Officer (Senior VP & Chief Med Officer)","officer_title":"Senior VP & Chief Med Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":10000.0,"shares_display":"10,000","price_per_share":30.0553,"price_display":"30.06","price_state":"stated","total_value":300553.0,"total_display":"300,553.00","shares_owned_after":18236.0,"shares_owned_after_display":"18,236","ownership_form":"D","is_10b5_1":null,"transaction_date":"2019-02-25","filed_date":"2019-02-27","scope":"insider"},{"id":6238142,"accession":"0001209191-18-053468","txn_seq":10,"anchor":"line-10","filing_url":"/filing/0001209191-18-053468","line_url":"/filing/0001209191-18-053468#line-10","is_derivative":false,"issuer_cik":"0001628738","issuer_name":"Audentes Therapeutics, Inc.","issuer_ticker":"BOLD","issuer_name_source":null,"issuer_url":"/issuer/0001628738","owner_cik":"0001679129","owner_name":"PRASAD SUYASH","owner_url":"/insider/0001679129","role":"Officer (Senior VP & Chief Med Officer)","officer_title":"Senior VP & Chief Med Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":4699.0,"shares_display":"4,699","price_per_share":35.5998,"price_display":"35.60","price_state":"stated","total_value":167283.4602,"total_display":"167,283.46","shares_owned_after":0.0,"shares_owned_after_display":"0","ownership_form":"D","is_10b5_1":null,"transaction_date":"2018-10-01","filed_date":"2018-10-02","scope":"insider"},{"id":6238139,"accession":"0001209191-18-053468","txn_seq":9,"anchor":"line-9","filing_url":"/filing/0001209191-18-053468","line_url":"/filing/0001209191-18-053468#line-9","is_derivative":false,"issuer_cik":"0001628738","issuer_name":"Audentes Therapeutics, Inc.","issuer_ticker":"BOLD","issuer_name_source":null,"issuer_url":"/issuer/0001628738","owner_cik":"0001679129","owner_name":"PRASAD SUYASH","owner_url":"/insider/0001679129","role":"Officer (Senior VP & Chief Med Officer)","officer_title":"Senior VP & Chief Med Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":3900.0,"shares_display":"3,900","price_per_share":37.8237,"price_display":"37.82","price_state":"stated","total_value":147512.43,"total_display":"147,512.43","shares_owned_after":0.0,"shares_owned_after_display":"0","ownership_form":"D","is_10b5_1":null,"transaction_date":"2018-10-01","filed_date":"2018-10-02","scope":"insider"},{"id":6238136,"accession":"0001209191-18-053468","txn_seq":8,"anchor":"line-8","filing_url":"/filing/0001209191-18-053468","line_url":"/filing/0001209191-18-053468#line-8","is_derivative":false,"issuer_cik":"0001628738","issuer_name":"Audentes Therapeutics, Inc.","issuer_ticker":"BOLD","issuer_name_source":null,"issuer_url":"/issuer/0001628738","owner_cik":"0001679129","owner_name":"PRASAD SUYASH","owner_url":"/insider/0001679129","role":"Officer (Senior VP & Chief Med Officer)","officer_title":"Senior VP & Chief Med Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":1101.0,"shares_display":"1,101","price_per_share":38.8533,"price_display":"38.85","price_state":"stated","total_value":42777.4833,"total_display":"42,777.48","shares_owned_after":0.0,"shares_owned_after_display":"0","ownership_form":"D","is_10b5_1":null,"transaction_date":"2018-10-01","filed_date":"2018-10-02","scope":"insider"},{"id":6238133,"accession":"0001209191-18-053468","txn_seq":7,"anchor":"line-7","filing_url":"/filing/0001209191-18-053468","line_url":"/filing/0001209191-18-053468#line-7","is_derivative":false,"issuer_cik":"0001628738","issuer_name":"Audentes Therapeutics, Inc.","issuer_ticker":"BOLD","issuer_name_source":null,"issuer_url":"/issuer/0001628738","owner_cik":"0001679129","owner_name":"PRASAD SUYASH","owner_url":"/insider/0001679129","role":"Officer (Senior VP & Chief Med Officer)","officer_title":"Senior VP & Chief Med Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":200.0,"shares_display":"200","price_per_share":36.315,"price_display":"36.32","price_state":"stated","total_value":7263.0,"total_display":"7,263.00","shares_owned_after":0.0,"shares_owned_after_display":"0","ownership_form":"D","is_10b5_1":null,"transaction_date":"2018-10-01","filed_date":"2018-10-02","scope":"insider"},{"id":6238129,"accession":"0001209191-18-053468","txn_seq":6,"anchor":"line-6","filing_url":"/filing/0001209191-18-053468","line_url":"/filing/0001209191-18-053468#line-6","is_derivative":false,"issuer_cik":"0001628738","issuer_name":"Audentes Therapeutics, Inc.","issuer_ticker":"BOLD","issuer_name_source":null,"issuer_url":"/issuer/0001628738","owner_cik":"0001679129","owner_name":"PRASAD SUYASH","owner_url":"/insider/0001679129","role":"Officer (Senior VP & Chief Med Officer)","officer_title":"Senior VP & Chief Med Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":100.0,"shares_display":"100","price_per_share":39.52,"price_display":"39.52","price_state":"stated","total_value":3952.0,"total_display":"3,952.00","shares_owned_after":0.0,"shares_owned_after_display":"0","ownership_form":"D","is_10b5_1":null,"transaction_date":"2018-10-01","filed_date":"2018-10-02","scope":"insider"},{"id":6634037,"accession":"0001209191-18-041769","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0001209191-18-041769","line_url":"/filing/0001209191-18-041769#line-4","is_derivative":false,"issuer_cik":"0001628738","issuer_name":"Audentes Therapeutics, Inc.","issuer_ticker":"BOLD","issuer_name_source":null,"issuer_url":"/issuer/0001628738","owner_cik":"0001679129","owner_name":"PRASAD SUYASH","owner_url":"/insider/0001679129","role":"Officer (Senior VP & Chief Med Officer)","officer_title":"Senior VP & Chief Med Officer","security_title":"Copmmon Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":5011.0,"shares_display":"5,011","price_per_share":38.7874,"price_display":"38.79","price_state":"stated","total_value":194363.6614,"total_display":"194,363.66","shares_owned_after":0.0,"shares_owned_after_display":"0","ownership_form":"D","is_10b5_1":null,"transaction_date":"2018-07-02","filed_date":"2018-07-05","scope":"insider"},{"id":6634034,"accession":"0001209191-18-041769","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001209191-18-041769","line_url":"/filing/0001209191-18-041769#line-3","is_derivative":false,"issuer_cik":"0001628738","issuer_name":"Audentes Therapeutics, Inc.","issuer_ticker":"BOLD","issuer_name_source":null,"issuer_url":"/issuer/0001628738","owner_cik":"0001679129","owner_name":"PRASAD SUYASH","owner_url":"/insider/0001679129","role":"Officer (Senior VP & Chief Med Officer)","officer_title":"Senior VP & Chief Med Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":4989.0,"shares_display":"4,989","price_per_share":38.0244,"price_display":"38.02","price_state":"stated","total_value":189703.7316,"total_display":"189,703.73","shares_owned_after":0.0,"shares_owned_after_display":"0","ownership_form":"D","is_10b5_1":null,"transaction_date":"2018-07-02","filed_date":"2018-07-05","scope":"insider"},{"id":6903226,"accession":"0001209191-18-022004","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001209191-18-022004","line_url":"/filing/0001209191-18-022004#line-3","is_derivative":false,"issuer_cik":"0001628738","issuer_name":"Audentes Therapeutics, Inc.","issuer_ticker":"BOLD","issuer_name_source":null,"issuer_url":"/issuer/0001628738","owner_cik":"0001679129","owner_name":"PRASAD SUYASH","owner_url":"/insider/0001679129","role":"Officer (Senior VP & Chief Med Officer)","officer_title":"Senior VP & Chief Med Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":1900.0,"shares_display":"1,900","price_per_share":30.0,"price_display":"30.00","price_state":"stated","total_value":57000.0,"total_display":"57,000.00","shares_owned_after":0.0,"shares_owned_after_display":"0","ownership_form":"D","is_10b5_1":null,"transaction_date":"2018-03-26","filed_date":"2018-03-28","scope":"insider"},{"id":4572465,"accession":"0001209191-17-063856","txn_seq":4,"anchor":"line-4","filing_url":"/filing/0001209191-17-063856","line_url":"/filing/0001209191-17-063856#line-4","is_derivative":false,"issuer_cik":"0001628738","issuer_name":"Audentes Therapeutics, Inc.","issuer_ticker":"BOLD","issuer_name_source":null,"issuer_url":"/issuer/0001628738","owner_cik":"0001679129","owner_name":"PRASAD SUYASH","owner_url":"/insider/0001679129","role":"Officer (Senior VP & Chief Med Officer)","officer_title":"Senior VP & Chief Med Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":6770.0,"shares_display":"6,770","price_per_share":28.451,"price_display":"28.45","price_state":"stated","total_value":192613.27,"total_display":"192,613.27","shares_owned_after":0.0,"shares_owned_after_display":"0","ownership_form":"D","is_10b5_1":null,"transaction_date":"2017-12-01","filed_date":"2017-12-05","scope":"insider"},{"id":4572461,"accession":"0001209191-17-063856","txn_seq":3,"anchor":"line-3","filing_url":"/filing/0001209191-17-063856","line_url":"/filing/0001209191-17-063856#line-3","is_derivative":false,"issuer_cik":"0001628738","issuer_name":"Audentes Therapeutics, Inc.","issuer_ticker":"BOLD","issuer_name_source":null,"issuer_url":"/issuer/0001628738","owner_cik":"0001679129","owner_name":"PRASAD SUYASH","owner_url":"/insider/0001679129","role":"Officer (Senior VP & Chief Med Officer)","officer_title":"Senior VP & Chief Med Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":1230.0,"shares_display":"1,230","price_per_share":28.9842,"price_display":"28.98","price_state":"stated","total_value":35650.566,"total_display":"35,650.57","shares_owned_after":0.0,"shares_owned_after_display":"0","ownership_form":"D","is_10b5_1":null,"transaction_date":"2017-12-01","filed_date":"2017-12-05","scope":"insider"},{"id":5037778,"accession":"0001209191-17-051077","txn_seq":2,"anchor":"line-2","filing_url":"/filing/0001209191-17-051077","line_url":"/filing/0001209191-17-051077#line-2","is_derivative":false,"issuer_cik":"0001628738","issuer_name":"Audentes Therapeutics, Inc.","issuer_ticker":"BOLD","issuer_name_source":null,"issuer_url":"/issuer/0001628738","owner_cik":"0001679129","owner_name":"PRASAD SUYASH","owner_url":"/insider/0001679129","role":"Officer (Senior VP & Chief Med Officer)","officer_title":"Senior VP & Chief Med Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":8000.0,"shares_display":"8,000","price_per_share":21.4351,"price_display":"21.44","price_state":"stated","total_value":171480.8,"total_display":"171,480.80","shares_owned_after":0.0,"shares_owned_after_display":"0","ownership_form":"D","is_10b5_1":null,"transaction_date":"2017-09-01","filed_date":"2017-09-01","scope":"insider"},{"id":6420931,"accession":"0001209191-18-022169","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001209191-18-022169","line_url":"/filing/0001209191-18-022169#line-1","is_derivative":false,"issuer_cik":"0001628738","issuer_name":"Audentes Therapeutics, Inc.","issuer_ticker":"BOLD","issuer_name_source":null,"issuer_url":"/issuer/0001628738","owner_cik":"0001679129","owner_name":"PRASAD SUYASH","owner_url":"/insider/0001679129","role":"Officer (Senior VP & Chief Med Officer)","officer_title":"Senior VP & Chief Med Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":7800.0,"shares_display":"7,800","price_per_share":30.025,"price_display":"30.02","price_state":"stated","total_value":234195.0,"total_display":"234,195.00","shares_owned_after":0.0,"shares_owned_after_display":"0","ownership_form":"D","is_10b5_1":null,"transaction_date":"2017-03-29","filed_date":"2018-03-29","scope":"insider"},{"id":6903217,"accession":"0001209191-18-022004","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001209191-18-022004","line_url":"/filing/0001209191-18-022004#line-1","is_derivative":false,"issuer_cik":"0001628738","issuer_name":"Audentes Therapeutics, Inc.","issuer_ticker":"BOLD","issuer_name_source":null,"issuer_url":"/issuer/0001628738","owner_cik":"0001679129","owner_name":"PRASAD SUYASH","owner_url":"/insider/0001679129","role":"Officer (Senior VP & Chief Med Officer)","officer_title":"Senior VP & Chief Med Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":300.0,"shares_display":"300","price_per_share":30.0,"price_display":"30.00","price_state":"stated","total_value":9000.0,"total_display":"9,000.00","shares_owned_after":0.0,"shares_owned_after_display":"0","ownership_form":"D","is_10b5_1":null,"transaction_date":"2017-03-27","filed_date":"2018-03-28","scope":"insider"}],"next_cursor":null,"ledger_fault":false,"count":{"value":28,"kind":"exact"},"open_market_only":false,"composition":{"kind":"exact","rows":[{"code":"P","label":"Open-market purchase","n":0,"open_market":true},{"code":"S","label":"Open-market sale","n":28,"open_market":true},{"code":"M","label":"Option exercise","n":0,"open_market":false},{"code":"A","label":"Grant or award","n":0,"open_market":false},{"code":"F","label":"Tax withholding","n":0,"open_market":false},{"code":"D","label":"Disposition to the issuer","n":0,"open_market":false},{"code":"X","label":"In-the-money option exercise","n":0,"open_market":false}],"total":28},"affiliations":[{"type":"issuer","type_label":"ISSUER","cik":"0001806310","name":"Taysha Gene Therapies, Inc.","url":"/issuer/0001806310","role":"Officer (CMO and Head of R&D)","n_filings":3,"first_seen":"2021-07-01","last_seen":"2022-07-07"},{"type":"issuer","type_label":"ISSUER","cik":"0001628738","name":"Audentes Therapeutics, Inc.","url":"/issuer/0001628738","role":"Officer (Senior VP & Chief Med Officer)","n_filings":8,"first_seen":"2017-09-01","last_seen":"2019-05-15"}],"order_statement":"Newest transaction date first, id breaking the tie.","canonical_url":"https://ebomi.com/insider/0001679129","retrieved_at":"2026-08-21T15:21:32+00:00","coverage":{"filings":1505395,"transactions":4290787,"issuers":28597,"insiders":152303,"first_filed_date":"2003-06-30","last_filed_date":"2026-08-20","last_ingest":"2026-08-21T05:23:33.898496+00:00","counts_are":{"filings":"estimate","transactions":"estimate","issuers":"estimate","insiders":"estimate"},"source":"SEC EDGAR Form 4 filings, parsed by ebomi","fault":false},"license":{"underlying_records":"US SEC filings are public records of the United States government and are not subject to copyright. The transactional facts in them are not ours to license.","this_presentation":"The parsing, normalisation, curation, and presentation are ebomi's own work.","grant":"undecided","grant_note":"The open licence for ebomi's own layer is an open owner decision (SPEC-20260731T1159Z open question 3: CC BY 4.0 or CC0 with a citation request). Until it is taken, no grant is asserted here.","citation_request":"Balogh, A. Insider trading. Scientific Data 10, 237 (2023)","url":"https://ebomi.com/license"},"fair_use":{"policy":"These JSON endpoints are open and unauthenticated. Please read them at a human pace, identify your client in the User-Agent header, and use the published dataset for bulk work rather than crawling page by page.","bulk_alternative":"doi:10.1038/s41597-023-02147-6"}}